Adrenal Insufficiency After Preoperative Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced Bladder Cancer: A Case Report.
Takahashi Takayuki T, Takamatsu Kimiharu K, Igarashi Daisuke D, Umezawa Yuta Y et al.
Enfortumab vedotin (EV) plus pembrolizumab is gaining widespread use in perioperative urothelial carcinoma management. However, perioperative immune-related adverse events (irAEs) may mimic postoperative complications, leading to diagnostic delays. A 79-year-old man with locally advanced bladder cancer (cT3bN0M0) received four cycles of EV plus pembrolizumab, followed by radical cystectomy with pathological complete response (ypT0N0). On postoperative Day 25, he developed fever, anorexia, and fatigue. Endocrine evaluation showed low adrenocorticotropic hormone and cortisol levels, leading to a diagnosis of adrenal insufficiency. Corticosteroid replacement therapy resulted in rapid clinical improvement. Adrenal insufficiency should be recognized as a potential irAE following immune checkpoint inhibitor (ICI) therapy. In patients with prior ICI exposure, nonspecific postoperative symptoms require a high index of suspicion and early endocrine evaluation.